This study is currently not recruiting new participants. Add it to your favourites and check back later.
Clinical Trial

Treatment of Steatohepatitis and Liver Fibrosis

Study Description

Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis. (TANDEM)

The purpose of this study is to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Tropifexor (LJN452)

Comparison with monotherapy and different combination doses

Drug - Cenicriviroc (CVC)

Comparison with monotherapy and different combination doses

Additional Information

Official Study Title

A Randomized, Double-blind, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis

Clinical Trial ID

NCT03517540

ParticipAid ID

mbkyJe